ADMA Biologics, Inc (ADMA) is a leading biotechnology business based in the US. It opened the day at $2.17 after a previous close of $2.17. During the day the price has varied from a low of $2.11 to a high of $2.235. The latest price was $2.2 (25 minute delay). ADMA Biologics is listed on the NASDAQ and employs 313 staff. All prices are listed in US Dollars.
Since the stock market crash in March caused by coronavirus, ADMA Biologics's share price has had significant negative movement.
Its last market close was $2.24, which is 38.96% down on its pre-crash value of $3.67 and 54.48% up on the lowest point reached during the March crash when the shares fell as low as $1.45.
If you had bought $1,000 worth of ADMA Biologics shares at the start of February 2020, those shares would have been worth $763.10 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $558.61.
|52-week range||$1.45 - $4.65|
|50-day moving average||$1.9924|
|200-day moving average||$2.4904|
|Wall St. target price||$8.29|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.243|
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
|1 week (2021-01-14)||4.27%|
|1 month (2020-12-22)||-0.90%|
|3 months (2020-10-22)||-3.93%|
|6 months (2020-07-22)||-27.15%|
|1 year (2020-01-21)||-50.45%|
|2 years (2019-01-18)||-34.52%|
|3 years (2018-01-19)||-37.85%|
|5 years (2016-01-21)||-63.33%|
|Revenue TTM||$40.3 million|
|Gross profit TTM||$-10,155,155|
|Return on assets TTM||-21.17%|
|Return on equity TTM||-124.48%|
|Market capitalisation||$203.3 million|
TTM: trailing 12 months
There are currently 12.0 million ADMA Biologics shares held short by investors – that's known as ADMA Biologics's "short interest". This figure is 0.2% up from 11.9 million last month.
There are a few different ways that this level of interest in shorting ADMA Biologics shares can be evaluated.
ADMA Biologics's "short interest ratio" (SIR) is the quantity of ADMA Biologics shares currently shorted divided by the average quantity of ADMA Biologics shares traded daily (recently around 3.5 million). ADMA Biologics's SIR currently stands at 3.45. In other words for every 100,000 ADMA Biologics shares traded daily on the market, roughly 3450 shares are currently held short.
However ADMA Biologics's short interest can also be evaluated against the total number of ADMA Biologics shares, or, against the total number of tradable ADMA Biologics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case ADMA Biologics's short interest could be expressed as 0.13% of the outstanding shares (for every 100,000 ADMA Biologics shares in existence, roughly 130 shares are currently held short) or 0.1685% of the tradable shares (for every 100,000 tradable ADMA Biologics shares, roughly 169 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against ADMA Biologics.
Find out more about how you can short ADMA Biologics stock.
We're not expecting ADMA Biologics to pay a dividend over the next 12 months. However, you can browse other dividend-paying shares in our guide.
Over the last 12 months, ADMA Biologics's shares have ranged in value from as little as $1.45 up to $4.65. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while ADMA Biologics's is 1.8761. This would suggest that ADMA Biologics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
ADMA Biologics, Inc., a biopharmaceutical and specialty immunoglobulin company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States. It offers BIVIGAM, an intravenous immune globulin product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, which is indicated for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company distributes its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was founded in 2004 and is headquartered in Ramsey, New Jersey.
Learn more about Transportation and Logistics Systems’ recent performance and where you can invest in Transportation and Logistics Systems shares. We also run through some helpful rules of thumb for any investor.
Learn more about Charlie’s Holdings’ recent performance and where you can invest in Charlie’s Holdings shares. We also run through some helpful rules of thumb for any investor.
Learn more about Lemonade’s recent performance and where you can invest in Lemonade shares. We also run through some helpful rules of thumb for any investor.
Learn more about Unity Software’s recent performance and where you can invest in Unity Software shares. We also run through some helpful rules of thumb for any investor
Learn more about FuelCell Energy’s recent performance and where you can invest in FuelCell Energy shares. We also run through some helpful rules of thumb for any investor.
Learn more about CloudCommerce’s recent performance and where you can invest in CloudCommerce shares. We also run through some helpful rules of thumb for any investor
Ever wondered how to buy shares in Zomedica Pharmaceuticals? We explain how and compare a range of providers that can give you access to many brands, including Zomedica Pharmaceuticals.
Ever wondered how to buy shares in YRC Worldwide? We explain how and compare a range of providers that can give you access to many brands, including YRC Worldwide.
Ever wondered how to buy shares in Xeros Technology Group? We explain how and compare a range of providers that can give you access to many brands, including Xeros Technology Group.
Ever wondered how to buy shares in Xpediator? We explain how and compare a range of providers that can give you access to many brands, including Xpediator.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.